Global contract pharmaceutical development and manufacturing organisation (CDMO), Almac Group, has completed a £20 million investment in its cold chain management capabilities with the opening of a facility in Northern Ireland.
Cold
The new cold store facility has been custom built and is 95,000 sq ft in size. It was built in response to customer requirements, including consideration to the rapidly growing are of orphan drug products, changes to regulatory compliance and a more stringent focus on data across the supply chain. Additionally, the further capacity offered by this new facility will facilitate scaling up of clients’ product portfolios in the biologic/biosimilar sector.
“Once again, Almac has set the industry standard with another significant investment in our comprehensive global clinical and commercial supply chain offering,” commented Alan Armstrong, CEO Almac Group. “This new facility at our global headquarters expands our cold storage capacity by 300% and our frozen storage capabilities by over 50%, enabling us to better serve our clients, and ultimately patients, worldwide thereby maintaining our position as a global leader in the life sciences sector.”
This news comes shortly after the company announced its £30 million investment into its new European campus, based in Dundalk, Ireland.